Tag:

Europe

Latest Headlines

Latest Headlines

Government attention yet to stop slide in U.K. pharma R&D investment

The United Kingdom government has made the life science industry a focal point of its turnaround strategy, but data that have dripped out over the past few months show companies are spending less and less on developing and manufacturing drugs in the state.

Ex-Elan execs target €325M IPO for life science fund

Former Elan CEO Kelly Martin and other people with links to the Irish drugmaker are aiming to raise up to €325 million ($364 million) in an IPO to bankroll their life science investment fund. The IPO on the Irish Stock Exchange could dwarf last year's listing by Circassia and become one of the biggest floats in European biotech history.

Woodford forms Imperial-heavy board, Prexton exits Serono's shadow, Chiesi bags stem cell nod

In this week's EuroBiotech Report, Woodford looks set to go all in on south east England's academic hotspots. The U.K. government is set to further bolster the credentials of the region by setting up an international dementia institute within 5 years and lending its support to a dementia R&D investment fund. Prexton Therapeutics grabbed a slice of the CNS funding that is available today, raising €8.7 million ($9.9 million) to take its Parkinson's disease candidate into the clinic. And more.

Wall Street endorses Cyberonics, Sorin $3B merger to become neuromodulation, cardiac surgery player

Neuromodulation company Cyberonics and cardiovascular device player Sorin in an all-stock deal that now values the combination at $3 billion.

Ex-Merck Serono team bags €8.7M for PhI Parkinson's program

Prexton Therapeutics, the first company to emerge from the €30 million ($34 million) biotech-creation program Merck Serono set up amid the shuttering of its Geneva R&D center, has closed a Series A round.

U.K. readies dementia R&D investment fund

Few could fault the United Kingdom for aiming too low. Having seen its CNS R&D chops whittled away by Big Pharma cuts, the U.K. government has decided the best way out of the mire is to take aim at one of the trickiest fields of all with a multimillion-pound dementia R&D investment fund.

Woodford loads board of new fund with 'golden triangle' vets

If anyone had doubts about exactly where Neil Woodford was going to aim the brunt of his new £200 million ($300 million) fund, details of the board that will oversee the venture will have washed away the uncertainty.

Ipsen picks up option to buy Canbex once PhIIa data rolls in

Ipsen has handed over €6 million ($6.8 million) for the option to buy British biotech Canbex Therapeutics.

UPDATED: Cellectis files for $115M IPO as CAR-T tech sizzles

PARIS-- Paris-based Cellectis has followed through with plans for an IPO in the U.S., filing Friday to raise $115 million in the hot American market as it pushes ahead on CAR-T research.

Novartis makes Israel a priority, U.K. dreams up Alzheimer's R&D hub, Shire defends tax model

In this week's EuroBiotech Report, Novartis is getting deeper into the Israeli biotech scene, tasking BioLineRx with keeping tabs on local startups after realizing it was underexposed to the country. Alzheimer's Research UK thinks it will find the next dementia drug in the "golden triangle" of Cambridge, London and Oxford. And more.